Marschall Alexander, Calva Freddy Delgado, Sánchez Inés Gómez, Velasco Elena Basabe, Martinez Manuel Tapia, Sánchez David Martí
Department of Cardiology, Central Defense Hospital, Madrid, Spain.
Department of Cardiology, University of Alcalá, Madrid, Spain.
J Cardiovasc Echogr. 2025 Jan-Mar;35(1):32-36. doi: 10.4103/jcecho.jcecho_28_24. Epub 2025 Apr 30.
Left ventricular global longitudinal strain (LV GLS) has shown to allow for risk stratification in heart failure (HF) patients with greater accuracy than LV ejection fraction (LVEF). However, previous studies included only few patients in New York Heart Association (NYHA) functional class I and rarely assessed clinical stability. The aim of this study was to determine the predictive value of LV GLS, as compared to LVEF, for short-term disease progression in asymptomatic stable HF patients.
This is a retrospective study including consecutive HF patients with LVEF <50%, in NYHA I, with no history of decompensation within the previous 6 months. The primary endpoint was the composite of cardiovascular death, hospitalization, and need for intensification of HF treatment within a 12-month follow-up period.
Out of 153 patients, 17.8% showed disease progression. Receiver operating characteristic curves identified GLS as the most accurate predictor for clinical progression (area under the curve [AUC]: 0.883 (95% confidence interval [CI]: 0.811-0.954), cutoff: -9.0%, sensitivity: 88.5%, and specificity: 88.5%). LVEF performed less precisely (AUC: 0.654 [95% CI: 0.527-0.782], cutoff: 42%, sensitivity: 70.4%, and specificity: 54%). Depressed GLS was a strong and significant predictor for disease progression (hazard ratio [HR]: 16.7 (95% CI: 6.2-35.1), < 0.001). Reduced LVEF showed to be a less reliable predictor (HR: 2.4 [95% CI: 1.1-5.2]).
GLS reliably predicts clinical progression in asymptomatic stable HF patients, with greater accuracy than LVEF. Its implementation in the risk stratification of these patients could help to identify those patients who are at greatest risk and may benefit from an intensification of their follow up and/or HF treatment.
左心室整体纵向应变(LV GLS)已被证明在心力衰竭(HF)患者的风险分层中比左心室射血分数(LVEF)具有更高的准确性。然而,先前的研究仅纳入了少数纽约心脏协会(NYHA)心功能I级的患者,并且很少评估临床稳定性。本研究的目的是确定与LVEF相比,LV GLS对无症状稳定HF患者短期疾病进展的预测价值。
这是一项回顾性研究,纳入了连续的LVEF<50%、NYHA I级且在过去6个月内无失代偿史的HF患者。主要终点是在12个月随访期内心血管死亡、住院以及强化HF治疗需求的复合终点。
153例患者中,17.8%出现疾病进展。受试者工作特征曲线确定GLS是临床进展最准确的预测指标(曲线下面积[AUC]:0.883(95%置信区间[CI]:0.811 - 0.954),截断值:-9.0%,敏感性:88.5%,特异性:88.5%)。LVEF的表现不太精确(AUC:0.654[95%CI:0.527 - 0.782],截断值:42%,敏感性:70.4%,特异性:54%)。GLS降低是疾病进展的一个强有力且显著的预测指标(风险比[HR]:16.7(95%CI:6.2 - 35.1),P<0.001)。LVEF降低显示为一个不太可靠的预测指标(HR:2.4[95%CI:1.1 - 5.2])。
GLS能可靠地预测无症状稳定HF患者的临床进展,比LVEF更准确。将其应用于这些患者的风险分层有助于识别那些风险最高且可能从强化随访和/或HF治疗中获益的患者。